Io Biotech, Inc. (IOBT) — SEC Filings
Io Biotech, Inc. (IOBT) — 42 SEC filings. Latest: 8-K (Mar 31, 2026). Includes 23 8-K, 6 10-Q, 6 SC 13G/A.
View Io Biotech, Inc. on SEC EDGAR
Overview
Io Biotech, Inc. (IOBT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 31, 2026: IO Biotech, Inc. filed an 8-K on March 31, 2026, reporting on several key events. These include potential bankruptcy or receivership proceedings, triggering events that could accelerate financial obligations, and changes related to directors or officers. The company also disclosed other events not c
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 4 bearish, 37 neutral, 1 mixed. The dominant filing sentiment for Io Biotech, Inc. is neutral.
Filing Type Overview
Io Biotech, Inc. (IOBT) has filed 23 8-K, 6 10-Q, 1 DEF 14A, 2 10-K, 6 SC 13G/A, 2 SC 13D/A, 1 DEFA14A, 1 10-K/A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of IOBT's 34 recent filings, 5 were flagged as high-risk, 14 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$57.016M |
| EPS | -$0.13 |
| Debt-to-Equity | N/A |
| Cash Position | $30.664M |
| Operating Margin | N/A |
| Total Assets | $39.956M |
| Total Debt | N/A |
Key Executives
- Barbara Fiorini
- B. Shayne Kennedy
- Barbara Fiorini Due
- B. Shayne Kennedy, Esq.
Industry Context
IO Biotech operates in the highly competitive clinical-stage biopharmaceutical sector, focusing on novel cancer vaccines. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Companies in this space often rely on platform technologies like IO Biotech's T-win to develop a pipeline of potential therapies.
Top Tags
corporate-governance (5) · 10-Q (4) · financials (4) · filing (3) · operations (3) · equity-sale (3) · financial-reporting (3) · sec-filing (3) · regulatory-filing (3) · IO Biotech (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-41008 | Identifies the company's filings with the SEC. |
| IRS Employer Identification No. | 87-0909276 | Company's tax identification number. |
| Commission File Number | 001-41008 | Identifies the company's filing with the SEC. |
| Net Loss | $57.016M | Net loss for the nine months ended September 30, 2025, an improvement from $64.158M in 2024. |
| Cash and Cash Equivalents | $30.664M | As of September 30, 2025, down from $60.031M at December 31, 2024. |
| Research and Development Expenses | $46.769M | For the nine months ended September 30, 2025, a decrease from $50.337M in 2024. |
| General and Administrative Expenses | $18.340M | For the nine months ended September 30, 2025, an increase from $17.897M in 2024. |
| Change in Fair Value of Warrants | $7.259M | Income recognized for the nine months ended September 30, 2025, compared to zero in 2024. |
| Proceeds from Issuance of Debt | $26.434M | Received during the nine months ended September 30, 2025. |
| Proceeds from At-the-Market Program | $6.572M | Received during the nine months ended September 30, 2025. |
| Accumulated Deficit | $416.329M | As of September 30, 2025, indicating significant historical losses. |
| Common Stock Shares Outstanding | 71,948,842 | As of November 10, 2025. |
| Net Loss Per Common Share | $0.13 | For the three months ended September 30, 2025, an improvement from $0.36 in 2024. |
| Cash and cash equivalents | $28.1M | Decreased from $60.0M at Dec 31, 2024, indicating rapid cash burn. |
| Net loss for six months | $48.6M | Increased from $40.1M in prior year, showing worsening profitability. |
Frequently Asked Questions
What are the latest SEC filings for Io Biotech, Inc. (IOBT)?
Io Biotech, Inc. has 42 recent SEC filings from Jan 2024 to Mar 2026, including 23 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IOBT filings?
Across 42 filings, the sentiment breakdown is: 4 bearish, 37 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Io Biotech, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Io Biotech, Inc. (IOBT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Io Biotech, Inc.?
Key financial highlights from Io Biotech, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IOBT?
The investment thesis for IOBT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Io Biotech, Inc.?
Key executives identified across Io Biotech, Inc.'s filings include Barbara Fiorini, B. Shayne Kennedy, Barbara Fiorini Due, B. Shayne Kennedy, Esq..
What are the main risk factors for Io Biotech, Inc. stock?
Of IOBT's 34 assessed filings, 5 were flagged high-risk, 14 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Io Biotech, Inc.?
Forward guidance and predictions for Io Biotech, Inc. are extracted from SEC filings as they are enriched.